Ibrutinib

Reasons behind ibrutinib discontinuation among patients with chronic lymphocytic leukemia

By

A tenth of patients with chronic lymphocytic leukemia (CLL) discontinued therapy with the Bruton tyrosine kinase inhibitor ibrutinib because of disease progression during clinical trials, according to a study.

Study identifies reasons for ibrutinib discontinuation in patients with chronic lymphocytic leukemia

Study identifies reasons for ibrutinib discontinuation in patients with chronic lymphocytic leukemia

About 10% of patients with chronic lymphocytic leukemia (CLL) treated with ibrutinib discontinued their therapy due to disease progression during clinical studies.

Rational drug combinations may overcome ibrutinib resistance

By

Genomic analyses of tumor and healthy tissue from patients with mantle cell lymphomas provided explanations for two types of resistance to ibrutinib and suggested ways to overcome them.

Resistance to ibrutinib in chronic lymphocytic leukemia explained

Resistance to ibrutinib in chronic lymphocytic leukemia explained

By

A new study has discovered how resistance develops in patients taking ibrutinib, a new and highly effective drug for the treatment of chronic lymphocytic leukemia.

FDA: ibrutinib approval to include CLL

FDA: ibrutinib approval to include CLL

Approval of ibrutinib (Imbruvica) has been expanded to include people with chronic lymphocytic leukemia.

Target of potent drug for chronic leukemia is confirmed

By

A new study helps confirm that a molecule targeted by the experimental drug ibrutinib is critical for the development of chronic lymphocytic leukemia, the most common form of adult leukemia.

Ibrutinib shows great promise in lymphoma, leukemia

By

Oral ibrutinib demonstrated durable single-agent efficacy in relapsed or refractory mantle-cell lymphoma in one study, and showed a high frequency of durable remissions in relapsed or refractory chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma in another study.

Sign Up for Free e-newsletters

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Genitourinary Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Rare Cancers Regimens
Skin Cancer Regimens Drugs